Trials / Active Not Recruiting
Active Not RecruitingNCT06608927
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 610 (estimated)
- Sponsor
- Arcus Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Quemliclustat | Administered as specified in the treatment arm |
| DRUG | Placebo | Administered as specified in the treatment arm |
| DRUG | Nab-paclitaxel | Administered as specified in the treatment arm |
| DRUG | Gemcitabine | Administered as specified in the treatment arm |
Timeline
- Start date
- 2024-12-13
- Primary completion
- 2030-11-30
- Completion
- 2030-11-30
- First posted
- 2024-09-23
- Last updated
- 2026-04-01
Locations
125 sites across 13 countries: United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Italy, Japan, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06608927. Inclusion in this directory is not an endorsement.